Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in ...
2 days ago · SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the ...
Alector’s AbbVie-Partnered Alzheimer’s Program Fails ... - BioSpace
1 day ago · Alector on Monday announced that its investigational antibody AL002 failed the Phase II INVOKE-2 study, as it did not significantly slow clinical progression in patients with Alzheimer’s disease. ... BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative ...
Alector stock drops after Alzheimer’s drug fails in Phase II trial
1 day ago · Alector’s internal pipeline suffered a blow as the Phase II INVOKE-2 trial evaluating its Alzheimer’s disease therapy, AL002, failed to meet the primary endpoint. The therapy failed to slow ...
Alector lays off 17% of staff after phase 2 Alzheimer's drug fail
1 day ago · Across both AL002 and AL003, the deal was worth up to $985.6 million in option exercise and milestone payments, with only paydays tied to AL002 remaining after the AL003 portion was axed.
AL002 Falls Short in Phase 2 INVOKE-2 Trial of Early Alzheimer …
2 days ago · AL002 did not meet the primary endpoint of slowing Alzheimer's clinical progression, as measured by the Clinical Dementia Rating Sum of Boxes and showed no treatment effects on secondary clinical and functional endpoints. ... News release. November 25, 2024.
ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study
Shares of Alector, Inc. ALEC were down 35.1% on Nov. 26 after the company announced data from a mid-stage study that evaluated its pipeline candidate, AL002, for treating individuals with early ...
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial
2 days ago · Patients were randomized to three dose regimens of AL002, 15mg/kg IV/q4w, 40mg/kg IV/q4w, 60mg/kg IV/q4w, or placebo. About Alector Alector is a clinical-stage biotechnology company that has ...
Alector Therapeutics’ novel Alzheimer's strategy fails in Phase 2
2 days ago · In the 381-person trial, however, patients who received AL002 didn’t decline more slowly than patients who were on placebo, as measured by a scale called the Clinical Dementia Rating Sum of Boxes.
Alector turns to layoffs as Alzheimer’s drug fails
2 days ago · For the past few years, researchers have been testing the medicine, known as AL002, in a clinical trial that enrolled close to 400 participants with early-stage Alzheimer’s. Results were made public Monday afternoon , and while Alector found a few positive signs, its medicine didn’t hit any of the trial’s key goals and was not ...
Alector AL002 INVOKE-2 Phase II Alzheimer’s trial misses goal
21 hours ago · US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). However, AL002 failed to meet the primary endpoint of slowing of Alzheimer’s clinical ...
- Some results have been removed